MKMehmet Karaçalı

Mehmet Karaçalı

*This is an algorithmically generated author record based on publicly available information.

Mehmet Karaçalı has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Consideration of Osteoporosis Risk in Selecting Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease Patients: Budesonide vs Fluticasone?

    by Ali Erol, Feridun Gürlek, Fatih Alp, Sümeyye Yaylacı, Enes Kocaman, Orkun- -Terzi, Şule Bilgin Kızıltaş, Mehmet Karaçalı, Neslihan Baykara Erol, Muhammed Fatih Şahin, et al.

    Objective: The use of medium and low-dose inhaled corticosteroids (ICS) did not increase the risk of osteoporosis in individuals with chronic obstructive pulmonary disease (COPD). The goal is to look at the risk of osteoporosis that comes with Budesonide and Fluticasone when choosing ICS for people with COPD, since this group of people is more likely to get osteoporosis. Methods: Patients with Stage E COPD who were on ICS and came to a tertiary healthcare facility between January 2024 and January 2025 were included. There were three groups in the trial: people with COPD who were taking inhaled budesonide, those who were on fluticasone, and a control group. Results: The study comprised 122 participants: 16 COPD patients utilizing inhaled fluticasone, 16 COPD patients utilizing inhaled budesonide, and 90 individuals in the control group. The mean age of the study participants was 72.79 years; the mean age of the fluticasone group was 74.69 years, the mean age of the budesonide group was 73.19 years, and the mean age of the control group was 72.38 years. The groups exhibit no significant difference for osteoporosis (p>0.05). No significant difference was seen between the groups for the duration and intensity of ICS use (p>0.05). Conclusion: In individuals with COPD, the administration of budesonide and fluticasone as inhaled corticosteroid options has not elevated the risk of osteoporosis.

  • Open Access

    Alteration in TSH levels during Ramadan in non fasting levothyroxine treated patients living with fasting family members

    by Alper Aytekin, İpEk Köroğlu, Zeynel Abidin Sayiner, Mehmet Karaçalı, Elif Melis Baloğlu Akyol, Ersin Akarsu

    Objectives: During Ramadan, lifestyle changes may affect thyroid function not only in fasting individuals but also in those who do not fast. This study examined the impact of Ramadan-related behavioral shifts on thyroid-stimulating hormone (TSH) levels in patients receiving stable levothyroxine therapy. Methods: This observational before-and-after study, conducted between January 2023 and January 2024, included 116 hypothyroid patients on stable levothyroxine (LT4) therapy. Serum TSH, free thyroxine (fT4), and free triiodothyronine (fT3) levels were measured one month before and within one week after Ramadan. Patients were categorized as fasting or non-fasting, and completed a structured questionnaire regarding medication timing, fasting behavior, and lifestyle changes. Linear regression analysis was used to identify predictors of post-Ramadan TSH changes. Results: TSH levels significantly increased after Ramadan in the overall cohort (mean±SD: 3.03±3.24 vs. 4.77±7.83 mU/L; P=0.028), while fT3 and fT4 levels remained unchanged (P=0.14 and P=0.72, respectively). Among fasting patients (n=72), TSH rose from 3.26±3.26 to 4.80±8.58 mU/L (P=0.47), whereas non-fasting patients (n=44) showed a significant increase from 2.65±3.21 to 4.73±6.51 mU/L (P=0.006). Polypharmacy was associated with increased odds of post-Ramadan TSH elevation (OR=2.67, 95% CI: 1.25–5.73, P=0.01). Among non-fasting patients, those who reported changes in sleep or meal patterns during Ramadan (n=28) experienced a significantly higher increase in TSH compared to those without such changes (ΔTSH: 2.47±3.88 vs. 0.81±2.12 mU/L, P=0.02). Conclusions: Patients receiving LT4 therapy who do not fast during Ramadan may still exhibit significant TSH variability, likely due to behavioral and circadian disruptions. These findings emphasize the importance of proactive monitoring and targeted education for all hypothyroid patients during Ramadan, irrespective of fasting status.